A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer

NCT05077449 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Breast Cancer

Interventions

DRUG: XZP-3287+Fulvestrant
DRUG: Placebo + Fulvestrant

Sponsor

Xuanzhu Biopharmaceutical Co., Ltd.